Ovarian carcinoma (high-grade serous predominant) · line 2 · Topotecan single-agent (platinum-resistant recurrent ovarian)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	palliative
Linked regimen	`REG-TOPOTECAN-OVARIAN`

ID	`IND-OVARIAN-2L-PLAT-RES-TOPOTECAN`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

ESCAT IIA. Salvage / palliative track when other platinum-resistant options exhausted or contraindicated.

Used By

Algorithms

ALGO-OVARIAN-2L - ALGO-OVARIAN-2L